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Abstract
Background: Previous trials have investigated the effect of  hepatitis C on lung functions; however, the role of  viral load levels 
is unclear. The aim of  this study was to investigate the effect of  HCV viremia status on lung functions.  
Methods: This study was in 60 patients with chronic hepatitis C (CHC). Patients were classified into three groups (non-viremic, 
low-viremic and high-viremic) based on serum HCV RNA levels. Spirometric parameters (FEV1, FVC, FEV1/FVC) and the 
proportion of  patients with spirometric abnormalities were compared between three groups.
Results: High-viremic and low-viremic patients showed a significantly higher prevalance of  spirometric abnormality than ob-
served in non-viremic patients (p=0.02). Moreover, there was a significant moderate correlation between viremia level and the 
percentage of  spirometric abnormalities (Cramer’s U value=0.452, p=0.002). High-viremic patients were 14.2 times more likely 
to exhibiting pulmonary dysfunction than non-viremic patients. Additionally, spirometric parameters FEV1 and FVC were sig-
nificantly reduced in high-viremic and low-viremic patients compared to those in non-viremic patients (p=0.013 and p<0.001 
respectively). 
Conclusion: These results indicate that persistent HCV infection may be associated with reduced pulmonary functions, espe-
cially in patients with high viremia levels. Therefore, these patients should be carefully monitored for lung function.
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Introduction
Hepatitis C virus (HCV) mainly affects the liver, but can 
also present with extra hepatic manifestations.1 One of  
the most important extrahepatic manifestations of  HCV 
is pulmonary involvement. In chronic hepatitis C (CHC)
patients, pulmonary involvement may emerge as inter-
stitial pneumonitis and fibrosis, initiation/exacerbation 
of  pre-existing chronic obstructive pulmonary disease 
(COPD) and asthma.2
The pulmonary involvements of  HCV infection are 
mostly asymptomatic and progressive.3,4 Therefore, the 
clinical progression of  HCV-related pulmonary disorders 
might contribute to increased mortality and morbidity of  
CHC infection, which indicates the importance of  early 
diagnosis of  HCV-related pulmonary disorders. Howev-
er, there is no consensus in the literature as to whether 
routine screening with pulmonary function tests (PFTs) 
would be beneficial in these patients. In addition, there 
are no data to identify those at high-risk of  lung involve-
ment. 
The aim of  this study was to explore the influence of  viral 
load level on pulmonary functions in CHC patients. This 
study may contribute to literature about whether routine 
screening for lung functions is necessary in CHC patients. 
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Study population and design
This prospective clinical study was carried out among 
the 60 CHC patients with and without viremia who were 
admitted to our clinic. The patients were divided into 
three groups based on serum HCV RNA levels. These 
groups were non-viremic (HCV RNA: negative), low-vi-
remic (HCV RNA<800.000 IU/ml) and high-viremic 
(HCV RNA≥800.000 IU/ml) groups.5 All non-viremic 
patients had previously received interferon(IFN) therapy 
for HCV infection. Spirometric PFTs were performed in 
all three groups. Forced vital capacity (FVC), forced ex-
piratory volume in the 1st second  (FEV1) and FEV1/
FVC were measured. All the tests were performed in the 
University hospital pulmonary function laboratory based 
on the ATS/ERS standard protocol using a Quark PFT 
device (Cosmed, Italy).6 All the tests were performed by 
the same technician using the same spirometer. Spiromet-
ric parameters (FEV1, FVC, FEV1/FVC) and the pro-
portion of  patients with spirometric abnormalitieswere 
compared between the three groups. The aspartate ami-
notransferase to platelet ratio index (APRI) was used to 
evaluate the liver fibrosis stages of  patients, which is a 
non-invasive alternative to liver biopsy. Blood samples 
were collected for the following parameters just before 
the spirometric tests; HCV RNA for viral load, AST level 
and platelet count. The upper limit of  normal (ULN) of  
AST was 40 IU/L. APRI scores were calculated as [( AST 
/ ULN AST ) X 100] / Platelet Count (109/L).7
Patients coinfected with hepatitis B, current smokers, 
COPD patients with an episode of  exacerbation and 
patients who were diagnosed as having an acute respira-
toryinfection were excluded from the study. To rule out 
the IFN therapy effect on lung functions, the participants 
who received IFN therapy within the last one year were 
also excluded. The presence of  previous chronic lung dis-
ease and previous smoking habits were also recorded.
Approval for the study was obtained from the ethics Com-
mittee of  Mustafa Kemal University School of  Medicine. 
Informed consent was obtained from all participants.
Definitions
CHC was defined by the presence of  the HCV antibody 
and the persistence of  detectable HCV RNA for at least 
six months. Patients who were negative for HCV RNA 
for at least six months were considered as non-viremic. 
Spirometric test results were considered normal if  the 
FEV1 and FVC were ≥80% of  the predicted value and 
the FEV1/FVC ratio was≥70%. Spirometric abnormali-
ties were defined as restrictive, obstructive and mixed pat-
terns. An obstructive pattern was defined as an FEV1/
FVC ratio below 70% of  the predicted value and an 
FEV1 below 80% of  the predicted value. A restrictive 
pattern was defined as a reduction in FVC and a normal 
FEV1/FVC ratio. A pattern of  combined obstructive 
and restrictive was defined as a mixed pattern.
Statistical analysis
Statistical analyses were performed using the SPSS soft-
ware version 21(SPSS Inc., Chicago, IL, USA). Normality 
tests were done by using Kolmogorov-Smirnov and Sha-
piro-Wilk’s tests. Categorical variables were compared by 
the Chi-square test or Fisher’s exact test, where appropri-
ate, between the groups. To determine an association be-
tween lung functions (FEV1, FVC, FEV1/FVC) / APRI 
scores and HCV viremia level (non-viremic, low-viremic 
or high-viremic) the Kruskal-Wallis test was used.The 
correlation between HCV viremic status/viremia level 
and the percentage of  spirometric abnormalities was test-
ed using the Chi-Square independence test. A Spearman’s 
Rank-Order Correlation was run to the relationship be-
tween APRI scores and lung functions. In all tests, p val-
ues <0.05 were considered to be statistically significant.To 
identify the predictive factor for spirometric abnormality, 
binary logistic regression analysis was performed. The 
Hosmer-Lemeshow goodness of  fit statistics was used to 
assess model fit. The Wald test was used to determine sta-
tistical significancefor each of  the independent variables. 
Charts were plotted using GraphPad Prism v7.0d for Mac 
(GrapPad Software, San Diego, CA, USA).
Results
The study included 31 patients without viremia, 15 pa-
tients with low viremia and 14 patients with high viremia. 
Of  the 60 patients, 48.3% were female and 51.7% were 
male. The median age of  the patients was 64.5 (range: 
38-74) years. The characteristics of  each group are shown 
in Table 1. 
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Table 1. Comparison of chronic hepatitis C patient groups according to epidemiological and 
pulmonary   function tests (N=60) 
 
 
a Chronic obstructive pulmonary disease, 9; Bronchial asthma, 6. 
b Percent of predicted value 
 Abbreviations: BMI, Body-mass index; FVC, Forced vital capacity; FEV1, Forced expiratory volume 


























Median (IQR) age, yr 62 (10.0) 67 (10.0) 66 (9.0) 0.106 
Male sex, n (%) 13 (41.9) 6 (40.0) 10 (71.4) 0.141 
Ex-smokers, n (%) 11 (35.5) 5 (33.3) 5 (35.7) 0.935 
Median (IQR) Pack-years 8.9 (12.3) 11 (17.6) 14.8 (21.3) 0.866 
Median (IQR) BMI, Kg/m2 28.5 (4.9) 29.3 (6.0) 28.8 (4.2) 0.823 
History of previous pulmonary 
disease, n (%) a 
5 (16.1) 4 (26.7) 6 (42.9) 0.157 
Pulmonary function tests     
Median (IQR) FEV1 b 86 (23.0) 76 (36.0) 67 (39.0) 0.013 
Median (IQR) FVCb 86 (19.0) 79 (34.0) 65 (19.0) <0.001 
Median (IQR) FEV1/FVCb 103 (28.0) 84 (35.0) 103 (47.5) 0.432 
Spirometric abnormality, n (%) 9 (29.0) 8 (53.3) 12 (85.7) 0.02 
Median (IQR) APRI 0.2 (0.12) 0.7 (0.65) 0.3 (0.6) <0.001 
There was no significant difference regarding age, gen-
der and body mass index (BMI) among the non-viremic, 
low-viremic and high-viremic groups (p>0.05 for all 
comparisons). The proportions of  ex-smokers and pre-
vious pulmonary disease history were similar across the 
three groups (p=0.935 and p=0.157 respectively). 
The most striking result to emerge from the data was that 
of  the 60 CHC patients, 29 (48.3%) had abnormal PFTs 
results, while only 15 (25%) had a history of  previous 
lung disease (9 patients with COPD and 6 patients had 
asthma). 
The proportion of  patients with spirometric abnormali-
ties was significantly lower in the non-viremic group than 
in the low-viremic and high-viremic groups (p=0.02)(Ta-
ble 1). Compared with patients without viremia, the per-
centages of  spirometric abnormalities increased gradually 
from low-viremic to high-viremicpatients (29%, 53.5% 
and 85.7% respectively). The Chi-Square Independence 
test showed a significant moderate correlation between 
viremia level and the percentage of  spirometric abnor-
malities (Cramer’s U value=0.452, p=0.002). A normal 
PFT result was determined in only a minority (14.3%) of  
high-viremic patients.
African Health Sciences Vol 19 Issue 2, June, 2019 1990
As shown in Figure 1 and Figure 2, the spirometric pa-
rameters FEV1 and FVC were significantly reduced in 
high-viremic and low-viremic patients compared to those 
in non-viremic patients (p=0.013 and p<0.001respective-
ly). There were no significant differences in FEV1/FVC 
ratio between the three groups (p=0.432)(Table 1).
PFT results showed a predominantly restrictive pulmo-
nary dysfunction (26.6%) followed by mixed pulmonary 
dysfunction (5%). The distribution of  pulmonary func-
tion patterns in the three groups is shown in Figure 3. 
The APRI scores were significantly lower in the non-vi-
remic group than in the low-viremic and high-viremic 
groups (p<0.001). However, there was no correlation 
between APRI scores and spirometric parameters FEV1, 
FVC, FEV1/FVC (Spearman correlation coefficients 
were -0.065, -0.081 and -0.170 respectively).
Logistic regression analysis was applied to ascertain the 
effects of  viremia level, age, BMI, gender and smoking 
history on the likelihood of  developing pulmonary dys-
function. The model explained 37% (Nagelkerke R 2) 
of  the variance in pulmonary dysfunction and correctly 
classified 70% of  cases. High viremic patients were 14.2 
times more likely to exhibiting pulmonary dysfunction 
than non-viremic patients. A high viremia level [odds ra-
tio (OR)=14.202, confidence interval (CI)=2.324-86.805; 
p=0.004] was found to be a significant predictive factor 
for the occurrence of  pulmonary dysfunction.
Discussion
There is increasing evidence suggesting that CHC infec-
tion can play an important role in interstitial pneumonitis, 
pulmonary fibrosis, the initiation/exacerbation of  pre-ex-
isting asthma and COPD.2  Previous research has demon-
strated that HCV-related pulmonary disorders are most-
ly asymptomatic, which means that these disorders are 
mostly underdiagnosed or delayed.3,8 On the other hand, 
pulmonary fibrosis causes a progressive and devastating 
loss of  pulmonary functions.4 Therefore, diagnosis of  
pulmonary involvement in the early stages is of  great im-
portance. To examine all HCV infected patients for lung 
function would not be cost-effective, so it is important 
to identify HCV-infected patients who are at increased 
risk of  pulmonary involvement. As, the prognostic rele-
vance of  baseline HCV RNA levels is known,whether or 
not there was a causal relationship between viral load lev-
els and pulmonary involvement was investigated in this 
study.9
The results of  the current study showed that the pres-
ence of  viremia is associated with an increased rate of  
pulmonary disorders, especially at high levels of  viremia.
Surprisingly, patients with high viremia were found to 
be 14.2 times more likely to have a spirometric abnor-
mality than non-viremic patients.Moreover, there was a 
moderate significant association between viral load level 
and the rate of  spirometric abnormalities. This associa-
tion may be explained by the greater number of  patients 
in the high-viremic group and low-viremic group with 
advanced hepatic fibrosis compared to the non-viremic 
groups. However, there was no association between 
APRI scores and lung functions. In accordance with the 
present results,recent studies using PFTs have failed to 
find any association between the severity of  hepatic dis-
ease and the presence of  interstitial lung changes.8,10 An-
other possible explanation for this is that if  HCV induces 
chronic inflammation in the lung, higher levels of  viremia 
might be associated with a higher degree of  inflammation 
and may contribute to the high rates of  pulmonary dis-
orders.11 This hypothesis was supported by the findings 
of  a prospective study conducted by Kanazawa et al who 
found that lung damage in viremic CHC patients can be 
reversed or returned to normal with successful eradica-
tion of  the HCV infection.12
In reviewing the literature, pulmonary dysfunction in 
CHC patients was predominantly restrictive as shown by 
Abbas et al.13 Similarly, in the current study, the most com-
monly detected spirometric abnormalities wererestrictive 
and mixed patterns.This result also supports previous re-
search into this issue which has linked CHC infection and 
interstitial lung disease.8,14
Another important finding in this study was that the spi-
rometric parameters, FEV1 and FVC, were significantly 
lower in high-viremicand low-viremic groups compared 
to thenon-viremic group. These findings suggested that 
a high viremia level is associated with reduced lung func-
tions in patients with CHC, and are consistent with those 
of  Ezzeldin et al who reported an association between 
the presence of  CHC infection and decline in lung func-
tions and also stated that treatment of  the CHC infection 
may improve pulmonary functions.15 Similarly, a 6- year 
follow up study,which confirmed this finding in asthmatic 
patients with CHC infection, showed that the annual de-
cline in DLCO was higher in IFN non-responders than 
IFN responders.4 However, the results of  that study were 
not compatible with those of  Foster et al who found no 
association between lung functions and viral load levels 
in CHC patients.16
In the current study, 48.3% of  the patients had an abnor-
African Health Sciences Vol 19 Issue 2, June, 20191991
mal PFT result, while only 25% had a history of  previous 
lung disease, which indicates that a large proportion of  
CHC patients have subclinical pulmonary disorders. This 
result is consistent with the findings of  a study by Erturk 
et al, which showed a high rate(75%) of  pulmonary dis-
orders in CHC patients without pulmonary symptoms.3
There were a number oflimitations in this study.First of  
all, the sample size is very small. This limitation means 
that study findings need to be interpreted cautiously. In 
addition, we have no histologic data for determine the 
stageof  liver fibrosis which might affect pulmonary func-
tions. Therefore, we used  APRI to evaluate liver fibrosis 
stages in CHC patients. Despite these limitations, this re-
search has highlighted the importance of  careful moni-
toring of  high-viremic CHC patients for lung functions, 
even if  they have no pulmonary symptoms. 
Conclusion
The results of  this study indicate that active HCV infec-
tion may be associated with reduced pulmonary functions, 
especially in patients with high viremia levels.In addition, 
the results of  this study further support the idea that 
CHC patients may have sub-clinical pulmonary disorders.
Therefore, these patients should be carefully monitored 
with regular PFTs for sub-clinical pulmonary disorders. 
Nevertheless, larger, prospective trials are needed to de-
termine whether there is a definitive causal relationship 
between HCV viral load levels and pulmonary disorders.
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